Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments.